| Title |
Page ID |
Namespace |
Size (bytes) |
Last change
|
| Blood–brain barrier |
84936 |
0 |
54393 |
20190117105105
|
| Intravenous therapy |
178769 |
0 |
40184 |
20190108160032
|
| Route of administration |
334816 |
0 |
29025 |
20190115070859
|
| Subcutaneous injection |
334820 |
0 |
4046 |
20190107095300
|
| Intramuscular injection |
334821 |
0 |
8579 |
20190107095300
|
| Therapeutic index |
334955 |
0 |
20399 |
20181231145536
|
| Injection |
665909 |
0 |
14929 |
20190111154901
|
| Cytochrome P450 |
709137 |
0 |
49994 |
20190117100127
|
| Therapeutic drug monitoring |
739219 |
0 |
4914 |
20181217063807
|
| Bioavailability |
769021 |
0 |
22147 |
20181204133035
|
| ADME |
826690 |
0 |
6152 |
20181208191145
|
| Bioequivalence |
998103 |
0 |
14201 |
20181202155139
|
| Prodrug |
1017427 |
0 |
12119 |
20190105155457
|
| Cimetidine |
1018112 |
0 |
50117 |
20190107221409
|
| CYP3A4 |
1024582 |
0 |
48387 |
20190117100132
|
| CYP2D6 |
1024815 |
0 |
29535 |
20190117100132
|
| CYP2E1 |
1024830 |
0 |
23203 |
20190117100132
|
| Polypharmacy |
1099391 |
0 |
25926 |
20190103145504
|
| Drug interaction |
1099396 |
0 |
44028 |
20190115190456
|
| Toxicokinetics |
1112289 |
0 |
3616 |
20181124175936
|
| Drug metabolism |
1173475 |
0 |
28070 |
20190117062839
|
| Toxication |
1173482 |
0 |
8800 |
20181117220121
|
| First pass effect |
1173539 |
0 |
4796 |
20181231150249
|
| Volume of distribution |
1272743 |
0 |
7013 |
20181109232927
|
| Aromatase |
1415048 |
0 |
27049 |
20190117100137
|
| Physiologically based pharmacokinetic modelling |
1566437 |
0 |
25277 |
20181117220123
|
| Effective half-life |
1728145 |
0 |
2594 |
20181010124401
|
| Drug action |
2070741 |
0 |
5915 |
20181221103905
|
| Polymersome |
2218269 |
0 |
6943 |
20180929133937
|
| Clearance |
2402393 |
0 |
13244 |
20190114112233
|
| Haber's rule |
2463278 |
0 |
3182 |
20181004165113
|
| CYP2A6 |
2516515 |
0 |
11644 |
20190117100155
|
| Enteric coating |
2910903 |
0 |
9850 |
20190113221504
|
| Trough level |
2962530 |
0 |
1936 |
20181010124518
|
| Biological half-life |
3206099 |
0 |
13872 |
20181117220129
|
| Loading dose |
3291372 |
0 |
3766 |
20181109232927
|
| Distribution |
3665681 |
0 |
9706 |
20181127032709
|
| Microdosing |
3845621 |
0 |
5774 |
20190114190444
|
| Ethnopsychopharmacology |
4189719 |
0 |
7015 |
20181014221721
|
| P450-containing systems |
4277840 |
0 |
10609 |
20190117100221
|
| CYP1A2 |
4320289 |
0 |
22911 |
20190117100221
|
| Epoxyeicosatrienoic acid |
4367754 |
0 |
49168 |
20190115133053
|
| Grapefruit–drug interactions |
4387617 |
0 |
55511 |
20181231234649
|
| Initial volume of distribution |
4629153 |
0 |
1687 |
20181221105004
|
| CYP2C9 |
4779665 |
0 |
27521 |
20190117100228
|
| CYP2C19 |
4779761 |
0 |
23851 |
20190117100228
|
| CYP2C8 |
4779795 |
0 |
13153 |
20190117100228
|
| Cytochrome P450 |
5119921 |
0 |
14296 |
20190117100234
|
| Enzyme induction and inhibition |
5245810 |
0 |
2570 |
20180929134736
|
| Context-sensitive half-life |
5507641 |
0 |
5320 |
20181222034944
|
| CYP1B1 |
5900320 |
0 |
8431 |
20190117100250
|
| CYP17A1 |
5914077 |
0 |
19201 |
20190117100250
|
| Plasma protein binding |
6025636 |
0 |
8443 |
20190114190623
|
| Binding potential |
6075099 |
0 |
5734 |
20180929134930
|
| Absorption |
6194872 |
0 |
8109 |
20181227105718
|
| Targeted drug delivery |
6470547 |
0 |
29101 |
20181117220136
|
| CYP27A1 |
6700732 |
0 |
10770 |
20190117100419
|
| Cholesterol side-chain cleavage enzyme |
6796314 |
0 |
22369 |
20190117100422
|
| Dosage form |
7481381 |
0 |
5887 |
20190112170427
|
| Osmotic-controlled release oral delivery system |
8031252 |
0 |
12541 |
20190107095300
|
| 21-Hydroxylase |
8852888 |
0 |
17070 |
20190117100519
|
| Modified-release dosage |
9360334 |
0 |
24525 |
20190115023910
|
| NONMEM |
9365585 |
0 |
2303 |
20181023170705
|
| Pharmacokinetics |
9674107 |
0 |
39961 |
20190111155232
|
| Cytochrome P450 reductase |
9736045 |
0 |
18592 |
20190117100553
|
| Pharmacometrics |
10162690 |
0 |
5168 |
20190108081442
|
| Dose |
10449471 |
0 |
19391 |
20181117220144
|
| CYP2B6 |
10456228 |
0 |
15614 |
20190117100638
|
| CYP3A7 |
10680502 |
0 |
2223 |
20190117100650
|
| Lanosterol 14 alpha-demethylase |
10906045 |
0 |
15122 |
20190117100705
|
| PEGylation |
10931846 |
0 |
17579 |
20181125212916
|
| Bolus |
12238660 |
0 |
4028 |
20190107095300
|
| Dissolution testing |
12458572 |
0 |
9824 |
20180727142641
|
| Flip-flop kinetics |
13589014 |
0 |
1806 |
20170925222345
|
| Dose dumping |
14007566 |
0 |
1873 |
20190105155735
|
| Cholesterol 24-hydroxylase |
14045189 |
0 |
18819 |
20190117100815
|
| IdMOC |
14350461 |
0 |
3830 |
20190116030740
|
| Ion trapping |
14440094 |
0 |
4782 |
20181030184709
|
| Active metabolite |
14564960 |
0 |
3539 |
20190116030743
|
| CYP3A |
14798557 |
0 |
8481 |
20190117100835
|
| Table of volume of distribution for drugs |
14848284 |
0 |
1952 |
20180929140604
|
| Compartment |
14848805 |
0 |
1715 |
20181109232927
|
| Table of medication secernated in kidney |
14848938 |
0 |
4653 |
20181026163436
|
| Skin popping |
15151817 |
0 |
2523 |
20190107135449
|
| Magnetic marker monitoring |
15342613 |
0 |
2193 |
20181010125624
|
| Simcyp Simulator |
16157480 |
0 |
3740 |
20180929140750
|
| Maintenance dose |
16698745 |
0 |
2530 |
20181109232927
|
| Free fraction |
16823207 |
0 |
3223 |
20181221113956
|
| CYP2C9*13 |
18420839 |
0 |
7711 |
20190117101022
|
| Rate of infusion |
18872320 |
0 |
1105 |
20181109232927
|
| Elimination rate constant |
19094964 |
0 |
3366 |
20181109232927
|
| Dermal patch |
20016657 |
0 |
1211 |
20190116030827
|
| CYP2C9*3 |
22685256 |
0 |
1478 |
20190117101216
|
| Chemotactic drug-targeting |
22787622 |
0 |
1696 |
20181221115703
|
| Cmin |
22982241 |
0 |
1264 |
20181222035059
|
| Cmax |
23184916 |
0 |
3490 |
20190114174555
|
| Area under the curve |
23518221 |
0 |
3802 |
20181109005510
|
| Bioanalysis |
23604382 |
0 |
6026 |
20180929142056
|
| Dihydromethysticin |
24225451 |
0 |
4389 |
20181223230630
|
| Plateau principle |
24608545 |
0 |
22889 |
20180522075742
|
| Epsilon-Viniferin |
24650277 |
0 |
7034 |
20181215042312
|
| Onset of action |
24697544 |
0 |
1906 |
20181222035104
|
| Intradermal injection |
25284347 |
0 |
3397 |
20181024105058
|
| Proadifen |
25296374 |
0 |
3252 |
20181214171239
|
| Amentoflavone |
26370272 |
0 |
6224 |
20190110031351
|
| PK/PD models |
26390451 |
0 |
5349 |
20181124062011
|
| Oculomucocutaneous syndrome |
28104937 |
0 |
1640 |
20190106161817
|
| Lipophilic efficiency |
28819446 |
0 |
5742 |
20181119052101
|
| Parallel artificial membrane permeability assay |
28893371 |
0 |
5083 |
20181117220204
|
| Cobicistat |
29240014 |
0 |
10662 |
20190111100418
|
| Cooperstown cocktail |
31190054 |
0 |
2748 |
20181221121832
|
| PottersWheel |
31376465 |
0 |
8275 |
20190115122951
|
| Rhapontigenin |
35281330 |
0 |
3510 |
20181214171240
|
| Blood–gas partition coefficient |
35737600 |
0 |
4185 |
20181205223518
|
| Liberation |
39490884 |
0 |
4011 |
20181222035144
|
| Elimination |
39490943 |
0 |
7081 |
20190116031029
|
| 20-Hydroxyeicosatetraenoic acid |
47836404 |
0 |
79670 |
20190115133053
|
| Epoxydocosapentaenoic acid |
49599350 |
0 |
15811 |
20181016222046
|
| Epoxyeicosatetraenoic acid |
49854427 |
0 |
23013 |
20180929145841
|
| Cytochrome P450 omega hydroxylase |
50110441 |
0 |
12100 |
20180929145902
|
| Residence time |
50390340 |
0 |
32156 |
20190110022349
|
| Variable volume pharmacokinetic models |
51553756 |
0 |
4901 |
20180929150119
|
| Intracerebroventricular injection |
53597220 |
0 |
2784 |
20181117220233
|
| Physical pharmacy |
57989671 |
0 |
2480 |
20190108191157
|
| Drug accumulation ratio |
57998655 |
0 |
315 |
20181010132647
|
| Cmean |
58105226 |
0 |
584 |
20181010132652
|
